Granules India Limited inaugurated two state-of-the-art Centres of Excellence at the Technology Research Park of IIT Hyderabad: the Ascelis Center of Excellence for Peptide Development and Characterization, and the Granules Center of Excellence for Particle Engineering. Dr. Krishna Prasad Chigurupati, Chairman and Managing Director of Granules India, Mrs. Uma Chigurupati, Executive Director, Granules India Limited, and Prof. B. S. Murty, Director of IIT Hyderabad, jointly led the inauguration ceremony.
Strengthening Peptide Innovation Through the Ascelis Centre
The Ascelis Center of Excellence for Peptide Development and Characterization is established under Ascelis Peptides, the company’s CDMO division. It will spearhead the development of cosmetic, therapeutic, and pharmaceutical peptides. As Ascelis’ first development and characterization facility in India, it is equipped for primary, secondary, and tertiary structure characterization. Moreover, the centre brings advanced analytical and process development expertise in-house. It will work closely with Senn Chemicals, the company’s Swiss-based R&D facility. This collaboration enhances Granules’ global peptide capabilities and reduces dependence on external partners.
Advancing Material Science with the Particle Engineering Centre
As per the press release, the Granules Center of Excellence for Particle Engineering will drive research in polymorphs and material sciences. It will also focus on novel drug delivery systems, including amorphous solid dispersions. The centre replaces earlier external and ad-hoc development efforts with a dedicated research platform. It will enable first-to-file opportunities and improve formulation performance. It will also support the development of proprietary technologies for regulated international markets.
Commitment to Scientific Excellence and Global Competitiveness
Speaking at the event, Dr. Krishna Prasad Chigurupati said, “Scientific excellence and rigorous research have always shaped our long-term strategy at Granules. The launch of these Centres of Excellence significantly strengthens our capabilities in peptides and advanced material sciences—areas that will define the next wave of pharmaceutical innovation. With specialised infrastructure and deep scientific expertise, we are enhancing our CDMO ambitions, accelerating breakthrough development, and building differentiated technologies that elevate our global competitiveness and deliver meaningful value to our partners and patients worldwide.”